Algorae Pharmaceuticals Limited

Algorae Pharmaceuticals Limited (1AI) formerly Living Cell Technologies (LCT) develops cell therapies to treat diseases with high unmet clinical needs. The Australasian biotechnology company is a global pioneer in the field of cell encapsulation and implantation for human therapeutics.

Contact Details

Level 7 , 330 Collins St MELBOURNE VIC 3000

1300 288 664

hello@automic.com.au

algoraepharma.com

Lists and Charts

Share price

Algorae Pharmaceuticals Limited

Closing price for the last 90 trading days

View ASX Chart

Total Shareholder Return as at 05/09/25

Rank	Company	1 Yr	5 Yr
955^th	Fisher & Paykel Healthcare Corporation	0.65%	1.05%
956^th	Aston Minerals	0.62%	-28.64%
957^th	Algorae Pharmaceuticals Limited	0.42%	-16.53%
958^th	EQ Resources	0.06%	7.88%
959^th	Sarytogan Graphite	0.06%	0%

View Full List

1713 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Company Share Transactions

Company Activity

	NEW ROLE: Vishal Shah,	22 Sep 2025
	NEW ROLE: Madhukar Bhalla,	05 Sep 2025
	NEW ROLE: Belinda Bartolo,	03 Jan 2023
	NEW ROLE: Daya Uka, Chief Financial Officer	24 Nov 2020
	NEW ROLE: Mark Licciardo, Company Secretary	03 Nov 2020
	NEW ROLE: Robert M Willcocks, Non-Executive Director	03 Nov 2020
	NEW ROLE: Carolyn M Sue, Non-Executive Director	03 Nov 2020
	NEW ROLE: Ken P Taylor, Chief Executive Officer, Executive Director	03 Nov 2020
	NEW ROLE: Bernard Tuch, Non-Executive Director, Interim Chairman	03 Nov 2020

Related Information

Access to our data for Algorae Pharmaceuticals Limited is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Algorae Pharmaceuticals Limited is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today